Hsbc Holdings PLC Boosts Stock Position in Humana Inc. (NYSE:HUM)

Hsbc Holdings PLC increased its holdings in Humana Inc. (NYSE:HUM) by 17.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 435,018 shares of the insurance provider’s stock after purchasing an additional 65,936 shares during the period. Hsbc Holdings PLC owned approximately 0.36% of Humana worth $163,093,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. increased its holdings in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the last quarter. Hantz Financial Services Inc. purchased a new position in Humana in the second quarter worth about $35,000. Family Firm Inc. bought a new stake in Humana during the second quarter worth approximately $37,000. Carolinas Wealth Consulting LLC raised its position in Humana by 274.1% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after purchasing an additional 74 shares during the period. Finally, Riverview Trust Co bought a new stake in shares of Humana in the 2nd quarter valued at approximately $44,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM opened at $315.29 on Thursday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The business’s fifty day simple moving average is $360.50 and its 200-day simple moving average is $346.16. The company has a market capitalization of $37.99 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 2.56 and a beta of 0.50. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $530.54.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the prior year, the business earned $8.94 EPS. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. On average, equities research analysts anticipate that Humana Inc. will post 16 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.12%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is 22.04%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Piper Sandler initiated coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 target price on the stock. Royal Bank of Canada boosted their price objective on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Baird R W upgraded shares of Humana to a “hold” rating in a report on Thursday, May 30th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. Finally, Oppenheimer increased their price objective on shares of Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Thirteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $398.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.